Abstract
Introduction
Clinical practice guidelines (CPGs) are one of the central topics of research in Artifical Intelligence in medicine. They can be described as "systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances" [3] . The major goal of CPGs is to support physicians in their daily work providing information needed for the decision-making process for a particular patient and disease. We can say that recommendations described in CPGs are one of the most important information sources to use during decision-making, because they provide phycisians various treatment options.
Recommendations are, in general, based on some kind of evidence, represented by different levels of evidence (LoEs), and on strengths of recommendations (SoRs). Several definitions of LoEs and SoRs exist by now. In the context of our work, the following definitions seem appropriate [2] :
Levels of evidence (LoEs): The validity of an individual study is based on an assessment of its study type. According to some methodologies, LoEs can refer not only to individual studies but also to the quality of evidence from multiple studies about a specific question or the quality of evidence supporting a clinical intervention.
Strengths of recommendation (SoRs):
The SoRs for clinical practice is based on a body of evidence. This approach takes into account the LoEs of individual studies, the type of outcomes measured by these studies, the number, consistency, and coherence of the evidence as a whole, the relationship between benefits, harms, and costs.
However, in addition to such graded recommendations, there also exist ungraded recommendations, where the guidelines do not contain any classification of the LoEs or SoRs. They usually appear in guidelines as ordinary text fragments. This circumstance makes the classification of ungraded evidence information a challenging task. Such a classification is necessary, because evidence-based recommendations, that are classified recommendations, are better followed in practice than recommendations not based on any scientific evidence [6] .
Hence, the aim is to present evidence information of CPGs in computer-interpretable form. Such a representation allow guideline users and modellers to embed the evidence information in several methods and tools and support the decision-making process.
Motivation
In order to facilitate the decision-making process, several guideline representation languages and systems have been developed. They provide physicians a computer interpretable representation of guidelines to enable automated decision-making support. However, LoEs and SoRs are inadequatly treated in guideline representation languages and tools, as they do not support the formalising and modeling process of recommendations with regard to the LoEs and SoRs sufficiently. They need to be extended to provide means for representing evidence information in CPGs. Therefore, a method is required to extend these guideline representation languages with the evidence information in computer-supported guidelines.
Guideline representation languages with well-structured syntax and semantics, such as Asbru [9] and PROforma [4] are of particular importance, because they have been developed to handle various concepts that care formalisation implies. Many guideline modelling tools (e.g., AsbruView, Tallis) are based on these languages. Our proposed extensions can be embedded into the syntax and semantic of these languages so that such tools can provide a computer-interpretable representation of the evidence information in CPGs. Hence, we decided to use Asbru and PROforma to model the evidence information according to our meta schema.
Asbru is a time-oriented, intention-based representation language to represent CPGs and clinical protocols in XML. It is used to represent guidelines in a set of hierarchical skeletal plans. Each plan consists of a name, a set of arguments, a time annotation, preferences, intentions, conditions, effects, and a plan body (for more detail consider [9, 8] ). The preferences are of particular importance to us, because they describe the resource constraints, the costs, and the responsible actor. Our meta schema will be embedded into the definitions of preferences.
PROforma is a guideline representation language to support the management of medical procedures as well as decision systems. It provides a basis for a method, a technology and different applications for developing and publishing executeable CPGs. A guideline application is modeled as a set of tasks and data items. The four basis classes are (1) plan, (2) decision, (3) action, and (4) enquiry (compare [11] ). In order to embed the evidence information into the PROforma syntax we focused on the decision task, because this task is responsible for the decision-making process during execution.
The way to the meta schema
We already stressed out the importance of a formal representation of evidence information in CPGs and analysed 21 CPGs developed by nine different organizations and co-operations. We manually extracted the data needed to embed the evidence information in CPGs into the representation languages Asbru and PROforma. The extracted data included information about the guideline developing organization (GDOs), LoEs, SoRs, trade-off between benefits and harms, and costs (for more detail compare [7] ).
Guideline developing organizations (GDOs)
: is essential to extract from and differentiate between the different grading systems. For example, the Finnish Medical Society Duodecim (FMSD) uses the letter A to grade a LoEs, whereas the Allergic Rhinitis and its Impact on Asthma Workshop Group (ARIA) uses the letter A to classify the SoRs.
Levels of evidence (LoEs): Our meta schema takes various types of medical studies into consideration and defines for each type of study different LoEs, indicating the quality of evidence on which the study is based. In order to get a hierarchical structure, we defined the LoEs on the basis of the study types, where meta-analysis is on the top and no study type at the bottom of the hierarchy. The type of a study is of particular importance to us, because it is going to be used to assign grades to ungraded evidence information. Classification system is important to establish a relation between the study type and the quality of evidence the study is based on. Therefore, we introduce our own labels (e.g., I 3, II 6) that consists of a Roman numeral indicating the type of study and a number indicating the quality of evidence the study is based on, separated by an underscore (for more detail see [7] ). This classification system will be used to formalize our meta schema and to extend the guideline representation languages Asbru and PROforma.
Strengths of recommendations (SoRs):
In most of the CPGs (16 guidelines out of 21) we considered, the SoRs are not explicitly represented. In the remaining five guidelines, different labels are used to refer to SoRs. Therefore, we developed our own meta schema for SoRs, which is compatible with the ones used in those five guidelines. It was clear that the SoRs have to be distinguishable, meaningful, clear, and unambiguous. We thought that more than four hierarchical levels would not satisfy these objectives and defined levels of strength as (1)strong recommendation, (2)recommendation, (3)weak recommendation, and (4)no recommendation.
Benefits and harms: Often CPGs contain texts about the benefits and possible harms of a particular treatment. The CPGs we used do not contain any information about the trade-off between the benefits and harms either. They only contain a common description of known benefits and harms. We used the well defined categorization by the GRADE working group as a basis for defining our meta schema for representing the trade-off between benefits and harms, because tehy suggest to include explicit information about the balance between the main health benefits of a treatment while considering its costs, as they may play a significant role during the decision-making process (see [1] ). We want this attribute to be included in the guideline representation languages.
Costs: CPGs have been developed to improve the quality of health care, while reducing avoidable costs for providing this health care. Therefore, it is important that guideline users are informed about the potential costs and expected outcomes of different choices regarding the treatment. This information allows users to prioritize different options for treatment according to their value and cost-effectiveness [5] .
Extension of Asbru and PROforma
In Section 3 we gave an overview of the basic attributes of evidence information we think to be mandatory when it is aimed to enable better support of physicians while decision-making. Now, we want to explain how they can be represented in the guideline representation languages Asbru and PROforma and how these languages have to be extended. In the following we summarise and name the seven attributes we propose: scientific conclusion: is the main attribute representing the overall result organization: represents the name of the guideline developing organization levels of evidence: contains the labels that refer to the type of study and the quality of its evidence (e.g., II 2, IV 3) study type: gives information about the concrete type of study (e.g., cohort study, etc.) strength: represents the stregnth of recommendation (e.g., strong recommendation) benefit harm: refers to the trade-off between benefits and harms of a treatment (only if available in the CPG)
costs: provides information about the costs of a particular treatment (only if available in the CPG)
The attributes organization, study type, strength, level of evidence, and scientific conclusion are essential, whereas benefit harm and costs are optional. Because Asbru and PROforma have their own syntax, it is necessary to propose the extension to both languages separately.
Extending Asbru
As Asbru is an XML-based language, we defined a Document Type Definition (DTD) that describes the use of our proposed seven attributes to formally represent evidence information in Asbru. The attribute scientific conclusion has to be included into the element preferences, which is a child of the plan element containing various information used in the plan selection phase (compare [8] ). The following XML representation is an example of a CPG modeled in Asbru. <preferences> <scientific conclusion organisation = "SIGN" level of evidence = "III 2" study type = "Randomized Controlled Trials" strength = "Strong Recommendation"> <costs name="monetary-costs"> <numerical-constant unit="Euro" value="1000"/> </costs> <costs name="discomfort"> <qualitative-constant value="low"/> </costs> </scientific conclusion> </preferences> This example states that, the guideline is developed by SIGN, whereas the medical recommendation is classified with III 2 referring to the study type Randomized Controlled Trials and indicating the strength Strong Recommendation. Its costs are estimated to be 1000 Euro per month, whereas the patient's discomfort will be at a low level [8] .
Extending PROforma
The syntax of PROforma is described using the Backus Naur Form (BNF). We use the same syntax to present our extension that can be embedded into PROforma. Here, the scientific conclusion attribute has to be embedded into the main definitions of the attribute argument in the PROforma syntax (compare [10] ).
<argument>::="argument"::"<scientific conclusion>","<expression> <scientific conclusion>::=<organisation><level of evidence><study type><strength> <scientific conclusion>::=[<benefit harm>] <scientific conclusion>::=[<cost>] <organisation>::=<atom> <level of evidence>::=<atom> (must be either "I 1", "I 2", "I 3", "I 4", "II 1", "II 2", "II 3", "II 4", "II 5", "II 6", "II 7", "III 1", "III 2", "III 3", "III 4", "III 5", "III 6", "III 7", "IV 1", "IV 2", "IV 3", "IV 4", "IV 5", "V 1", "V 2", "V 3", "V 4", "V 5", "VI 1", "VII 1", "VII 2" or "VII 3") <study type>::=<atom> (must be either "Meta Analysis", "Systematic Reviews", "Randomized Controlled Trials", "Cohort Studies", "Case Control Studies", "Expert Opinion", "No Study Type") <strength>::=<atom> (must be either "Strong Recommendation", "Recommendation", "Weak Recommendation", "No Recommendation") <benefit harm>::=<atom> <benefit harm>::=<empty> <cost>::=<atom> <cost>::=<empty>
Evaluation
To evaluate the motivation to our meta schema, the grading schema itself, and the proposed extensions to Asbru and PROforma, we composed a questionnaire of ten questions. They were about the correctness, feasibility, and understandability of, the hierarchical structure of our meta schema, the proposed LoEs and SoRs, the mappings between existing grading schemes and our schema, the attribute representing the trade-off between benefits and harms, and the assignment of our LoEs and SoRs to ungraded evidence information. We also formulated questions regarding the availability of needed information for the proposed attributes, the expected extent of facilitation of the decison-making process when using our grading schema, and the representability of our schema with regard to existing grading schemes.
We sent this questionnaire to 29 persons including guideline developers, physicians, and developers of guideline representation languages. Most of them agreed with the correctness, understandability, and sensibility of the hierarchical structure, the quality of the LoEs and the SoRs, and the mapping tables for our schema. Some of them disagreed with the assignment of the SoRs to the ungraded evidence information. They believe that more information is needed than the LoEs and the SoRs to support a correct decision. We took all received answers into consideration to update our grading schema and representations, which yield to the enhanced version of our grading schema that we presented in this work.
Conclusion and future work
Our meta schema connects different schemes of LoEs and SoRs and provides a means to assign a LoE and a SoR to ungraded evidence recommendations based on the study type and quality of evidence if available. The meta schema provides a possibility to handle the multitude of grading systems on an equal level and facilitates the flow of the underlying information to be quickly and traceable. Additionally, evidence information about a particular recommendation provides guideline users the facility to choose between recommendations with high level and recommendations with lower level during decision-making. In this paper, we presented two extensions to the guideline representation languages Asbru and PROforma, to enable them to represent evidence information according to our proposed meta schema. We think that these extensions are essential to facilitate the decision-making process in computer-based medical treatment planning.
For the near future, our focus is on enhancing our meta schema in order to apply it to guidelines from other domains (e.g., cancer) and on developing Information Extraction methods that are able to (semi-) automatically extract evidence information in CPGs according to our proposed meta schema.
